4//SEC Filing
Bucher James B 4
Accession 0001209191-19-026033
CIK 0001423824other
Filed
Apr 24, 8:00 PM ET
Accepted
Apr 25, 6:43 PM ET
Size
7.4 KB
Accession
0001209191-19-026033
Insider Transaction Report
Form 4
Bucher James B
Sr. VP & General Counsel
Transactions
- Award
Common Stock
2019-04-23+7,810→ 11,706 total - Sale
Common Stock
2019-04-25$13.85/sh−1,897$26,281→ 9,809 total
Footnotes (2)
- [F1]On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 23,429 shares of Issuer's Common Stock (the "RSU"). Up to 7,810 shares subject to the RSU vest upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the "FDA") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the "FDA Filing Milestone") and the remaining shares subject to the RSU vest upon certain other performance criteria. On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 7,810 shares subject to the RSU.
- [F2]Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSU. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Documents
Issuer
ALDER BIOPHARMACEUTICALS INC
CIK 0001423824
Entity typeother
Related Parties
1- filerCIK 0001664928
Filing Metadata
- Form type
- 4
- Filed
- Apr 24, 8:00 PM ET
- Accepted
- Apr 25, 6:43 PM ET
- Size
- 7.4 KB